In this video, ZS principal Ed Schoonveld responds to highly critical payer feedback on pharma evidence dossiers. He addresses questions such as:
- Are pharma companies carefully considering the impact of more robust evidence options or racing to the market with a drug that customers don’t want?
- Are companies considering all access journey customer decisions and their evidence needs that ultimately impact how many patients will have access to the drug?
- Are companies truly considering the value needs of their customers?
Watch the video to learn ways pharma companies can strengthen evidence in trade-off with speed to launch and investment needs.